Bill & Melinda Gates Foundation

Antibody-drug conjugate (ADC) developer Adcendo has been busy during the last year and a half since the company raised a €31m ($32.3m) extension of the €51m ($53.2m) series A it originally raised in 2

Bain Capital Life Sciences (BCLS) raised its largest investment fund yet, nearly doubling the amount of money it has at its disposal to back both private and public drug developers, medical device and

Lykos Therapeutics , still reeling from US Food and Drug Administration rejection of the company’s capsule formulation of the psychedelic drug midomafetamine for the treatment of post-traumatic stress

A high-profile biopharma panel that included Nobel Laureate Professor Jack W. Szostak recently discussed how India could invigorate its innovation ecosystem and support cutting-edge R&D. The prescript